A phase 2 trial of Neurocrine’s Ingrezza in Tourette syndrome has missed its primary endpoint.

When there are financial ties between researchers working on a clinical study and the drug industry, the data from these tests are more likely to be positive,…

Women’s health biotech ObsEva has set the terms for an IPO that could net it in the region of $87 million.

President-elect Trump’s pick for HHS secretary bought shares in Zimmer Biomet, then introduced a bill that would have directly helped the company.

Alcobra took a body blow last year when the FDA placed a clinical hold on its lead drug metadoxine, but a failed phase 3 trial has now delivered a coup de…

Novartis-backed biotech Ophthotech is to make swingeing cuts to its staff as it reels from two pivotal late-stage failures for its experimental eye drug…

Evotec and MaRS Innovation have joined forces to found Fibrocor Therapeutics, a fibrotic disease startup.

Researchers led by Princeton have found a clue that could lead to a targeted treatment for Hepatitis E, a liver virus that causes 20 million infections a year.

The J.P. Morgan event is known as the event for biotech and the investor community and, although typically aimed at generalists, bio journalists are always on…